&nbsp;

Dec 2022

Drug

erlotinib

Other Name(s): Tarceva®

Quick Link(s):

Oct 2022

Drug

PERTuzumab

Other Name(s): Perjeta®

Quick Link(s):

Sep 2022

Regimen

ERLO

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Funding:

Exceptional Access Program

erlotinib - Incurable progressive NSCLC, with specific criteria

Drugs Used:

erlotinib

Quick Link(s):

Regimen Monograph

Oct 2022

Regimen

ENZL

Cancer Type:

Genitourinary,

Prostate

Intent: Palliative

Funding:

Exceptional Access Program

enzalutamide - For the treatment of metastatic castrate-resistant prostate cancer (mCRPC), with specific clinical criteria

Exceptional Access Program

enzalutamide - For the treatment of high risk non-metastatic castration-resistant prostate cancer (nmCRPC), with specific clinical criteria

Exceptional Access Program

enzalutamide - For the treatment metastatic castration sensitive prostate cancer (mCSPC), with specific clinical criteria

Drugs Used:

enzalutamide

Quick Link(s):

Regimen Monograph

Apr 2022

Regimen

PACL+PERT+TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2022

Regimen

PACL(W)+TRAS

Cancer Type:

Breast

Intent: Adjuvant

Funding:

New Drug Funding Program

Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer

Drugs Used:

PACLitaxel,

trastuzumab

Quick Link(s):

Regimen Monograph

Feb 2022

Regimen

PACL(W)+PERT+TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

Drugs Used:

Quick Link(s):

Regimen Monograph

Sep 2022

Regimen

ERLO

Cancer Type:

Head and Neck

Intent: Palliative

Drugs Used:

erlotinib (Unfunded)

Quick Link(s):

Regimen Monograph

Oct 2022

Regimen

ERLO

Cancer Type:

Gynecologic,

Vulva

Intent: Palliative

Drugs Used:

erlotinib (Unfunded)

Quick Link(s):

Regimen Monograph

Oct 2022

Regimen

PERT+TRAS

Cancer Type:

Breast

Intent: Palliative

Funding:

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

New Drug Funding Program

Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer

Drugs Used:

PERTuzumab,

trastuzumab

Quick Link(s):

Regimen Monograph

Sep 2022

Drug

pegaspargase

Other Name(s): Oncaspar®

Quick Link(s):